Works by Rasco, Drew

Results: 23

Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Published in:

2022

By:

Patnaik, Amita;
Gadgeel, Shirish;
Papadopoulos, Kyriakos P.;
Rasco, Drew W.;
Haas, Naomi B.;
Der-Torossian, Hirak;
Faltaos, Demiana;
Potvin, Diane;
Tassell, Vanessa;
Tawashi, Manal;
Chao, Richard;
O'Dwyer, Peter J.

Publication type:

Correction Notice

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Published in:

Targeted Oncology, 2022, v. 17, n. 2, p. 125, doi. 10.1007/s11523-022-00875-0

By:

Patnaik, Amita;
Gadgeel, Shirish;
Papadopoulos, Kyriakos P.;
Rasco, Drew W.;
Haas, Naomi B.;
Der-Torossian, Hirak;
Faltaos, Demiana;
Potvin, Diane;
Tassell, Vanessa;
Tawashi, Manal;
Chao, Richard;
O'Dwyer, Peter J.

Publication type:

Article

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Published in:

2018

By:

Goss, Glenwood D.;
Vokes, Everett E.;
Gordon, Michael S.;
Gandhi, Leena;
Papadopoulos, Kyriakos P.;
Rasco, Drew W.;
Fischer, JuDee S.;
Chu, Katharine L.;
Ames, William W.;
Mittapalli, Rajendar K.;
Lee, Ho‐Jin;
Zeng, Jiewei;
Roberts‐Rapp, Lisa A.;
Loberg, Lise I.;
Ansell, Peter J.;
Reilly, Edward B.;
Ocampo, Christopher J.;
Holen, Kyle D.;
Tolcher, Anthony W.;
Lee, Ho-Jin

Publication type:

journal article

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Published in:

Oncology, 2019, v. 97, n. 2, p. 102, doi. 10.1159/000500571

By:

Hong, David;
Rasco, Drew;
Veeder, Michael;
Luke, Jason J.;
Chandler, Jason;
Balmanoukian, Ani;
George, Thomas J.;
Munster, Pamela;
Berlin, Jordan D.;
Gutierrez, Martin;
Mita, Alain;
Wakelee, Heather;
Samakoglu, Selda;
Guan, Shanhong;
Dimery, Isaiah;
Graef, Thorsten;
Borazanci, Erkut

Publication type:

Article

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 329, doi. 10.1007/s00280-023-04613-9

By:

Biesdorf, Carla;
Guan, Xiaowen;
Siddani, Satya R.;
Hoffman, David;
Boehm, Nils;
Medeiros, Bruno C.;
Doi, Toshihiko;
de Jonge, Maja;
Rasco, Drew;
Menon, Rajeev M.;
Polepally, Akshanth R.

Publication type:

Article

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 1, p. 15, doi. 10.1007/s00280-023-04544-5

By:

Rasco, Drew W.;
Medina, Theresa;
Corrie, Pippa;
Pavlick, Anna C.;
Middleton, Mark R.;
Lorigan, Paul;
Hebert, Chris;
Plummer, Ruth;
Larkin, James;
Agarwala, Sanjiv S.;
Daud, Adil I.;
Qiu, Jiaheng;
Bozon, Viviana;
Kneissl, Michelle;
Barry, Elly;
Olszanski, Anthony J.

Publication type:

Article

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.

Published in:

Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 93, doi. 10.1007/s00280-021-04358-3

By:

Patnaik, Amita;
Weiss, Glen J.;
Rasco, Drew W.;
Blaydorn, Lisa;
Mirabella, Amy;
Beeram, Murali;
Guo, Wei;
Lu, Sharon;
Danaee, Hadi;
McEachern, Kristen;
Im, Ellie;
Sachdev, Jasgit C.

Publication type:

Article

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Published in:

2018

By:

Patnaik, Amita;
Papadopoulos, Kyriakos P.;
Rasco, Drew;
Beeram, Muralidhar;
Gordon, Michael;
Tsai, Frank;
Fu, Siqing;
Janku, Filip;
Hong, David;
Hynes, Scott M.;
Gundala, Sushma R.;
Willard, Melinda D.;
Zhang, Wei;
Lin, Aimee Bence

Publication type:

journal article

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Published in:

2018

By:

Patnaik, Amita;
Papadopoulous, Kyri;
Rasco, Drew;
Beeram, S. Muralidhar;
Gordon, Michael;
Tsai, Frank;
Fu, Siqing;
Janku, Filip;
Hong, David;
Hynes, Scott M.;
Gundala, Sushma R.;
Willard, Melinda D.;
Zhang, Wei;
Lin, Aimee Bence;
Papadopoulos, Kyriakos P;
Beeram, Muralidhar

Publication type:

journal article

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Published in:

2016

By:

Patnaik, Amita;
Tolcher, Anthony;
Papadopoulos, Kyriakos;
Beeram, Murali;
Rasco, Drew;
Werner, Theresa;
Bauman, John;
Scheuber, Anita;
Cox, Donna;
Patel, Bela;
Zhou, YanYan;
Hamid, Mohammed;
Schramek, Daniel;
Sharma, Sunil;
Papadopoulos, Kyriakos P;
Werner, Theresa L;
Bauman, John W;
Cox, Donna S;
Patel, Bela R

Publication type:

journal article

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 887, doi. 10.1007/s00280-015-2712-0

By:

Papadopoulos, Kyriakos;
Isaacs, Randi;
Bilic, Sanela;
Kentsch, Kerstin;
Huet, Heather;
Hofmann, Matthias;
Rasco, Drew;
Kundamal, Nicole;
Tang, Zhongwhen;
Cooksey, Jennifer;
Mahipal, Amit

Publication type:

Article

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.

Published in:

2015

By:

Papadopoulos, Kyriakos P;
Isaacs, Randi;
Bilic, Sanela;
Kentsch, Kerstin;
Huet, Heather A;
Hofmann, Matthias;
Rasco, Drew;
Kundamal, Nicole;
Tang, Zhongwhen;
Cooksey, Jennifer;
Mahipal, Amit

Publication type:

journal article

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 1, p. 183, doi. 10.1007/s00280-014-2615-5

By:

Tolcher, Anthony;
Patnaik, Amita;
Papadopoulos, Kyriakos;
Rasco, Drew;
Becerra, Carlos;
Allred, Alicia;
Orford, Keith;
Aktan, Gursel;
Ferron-Brady, Geraldine;
Ibrahim, Nageatte;
Gauvin, Jennifer;
Motwani, Monica;
Cornfeld, Mark

Publication type:

Article

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 363, doi. 10.1007/s00280-013-2361-0

By:

Tolcher, Anthony;
Rodrigueza, Wendi;
Rasco, Drew;
Patnaik, Amita;
Papadopoulos, Kyriakos;
Amaya, Alex;
Moore, Timothy;
Gaylor, Shari;
Bisgaier, Charles;
Sooch, Mina;
Woolliscroft, Michael;
Messmann, Richard

Publication type:

Article

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Published in:

Journal of Clinical Pharmacology, 2018, v. 58, n. 2, p. 180, doi. 10.1002/jcph.988

By:

Gupta, Neeraj;
Hanley, Michael J.;
Venkatakrishnan, Karthik;
Bessudo, Alberto;
Rasco, Drew W.;
Sharma, Sunil;
O'Neil, Bert H.;
Wang, Bingxia;
Liu, Guohui;
Ke, Alice;
Patel, Chirag;
Rowland Yeo, Karen;
Xia, Cindy;
Zhang, Xiaoquan;
Esseltine, Dixie‐Lee;
Nemunaitis, John

Publication type:

Article

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.

Published in:

Cancers, 2022, v. 14, n. 20, p. 4996, doi. 10.3390/cancers14204996

By:

Patnaik, Amita;
Hamilton, Erika;
Xing, Yan;
Rasco, Drew W.;
Smith, Lon;
Lee, Ya-Li;
Fang, Steven;
Wei, Jiao;
Hui, Ai-Min

Publication type:

Article

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

Published in:

Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325

By:

Tolcher, Anthony;
Flaherty, Keith;
Shapiro, Geoffrey I.;
Berlin, Jordan;
Witzig, Thomas;
Habermann, Thomas;
Bullock, Andrea;
Rock, Edwin;
Elekes, Agnes;
Lin, Chester;
Kostic, Dusan;
Ohi, Naoto;
Rasco, Drew;
Papadopoulos, Kyriakos P.;
Patnaik, Amita;
Smith, Lon;
Cote, Gregory M.

Publication type:

Article

The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research.

Published in:

Oncologist, 2009, v. 14, n. 5, p. 468, doi. 10.1634/theoncologist.2008-0268

By:

RASCO, DREW W.;
YANG XIE;
JINGSHENG YAN;
SAYNE, JENNIFER R.;
SKINNER, CELETTE SUGG;
DOWELL, JONATHAN E.;
GERBER, DAVID E.

Publication type:

Article

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181).

Published in:

CTS: Clinical & Translational Science, 2021, v. 14, n. 1, p. 277, doi. 10.1111/cts.12855

By:

Powderly, John;
Spira, Alexander;
Kondo, Shunsuke;
Doi, Toshihiko;
Luke, Jason J.;
Rasco, Drew;
Gao, Bo;
Tanner, Minna;
Cassier, Philippe A.;
Gazzah, Anas;
Italiano, Antoine;
Tosi, Diego;
Afar, Daniel E.;
Parikh, Apurvasena;
Engelhardt, Benjamin;
Englert, Stefan;
Lambert, Stacie L.;
Kasichayanula, Sreeneeranj;
Mensing, Sven;
Menon, Rajeev

Publication type:

Article

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 3, p. 241, doi. 10.1007/s10637-024-01428-0

By:

Chénard-Poirier, Maxime;
Hansen, Aaron R.;
Gutierrez, Martin E.;
Rasco, Drew;
Xing, Yan;
Chen, Lin-Chi;
Zhou, Heng;
Webber, Andrea L.;
Freshwater, Tomoko;
Sharma, Manish R.

Publication type:

Article

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 762, doi. 10.1007/s10637-022-01247-1

By:

LoRusso, Patricia;
Ratain, Mark J.;
Doi, Toshihiko;
Rasco, Drew W.;
de Jonge, Maja J. A.;
Moreno, Victor;
Carneiro, Benedito A.;
Devriese, Lot A.;
Petrich, Adam;
Modi, Dimple;
Morgan-Lappe, Susan;
Nuthalapati, Silpa;
Motwani, Monica;
Dunbar, Martin;
Glasgow, Jaimee;
Medeiros, Bruno C.;
Calvo, Emiliano

Publication type:

Article

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.

Published in:

Investigational New Drugs, 2017, v. 35, n. 2, p. 189, doi. 10.1007/s10637-016-0409-9

By:

Cleary, James;
Rosen, Lee;
Yoshida, Kenichiro;
Rasco, Drew;
Shapiro, Geoffrey;
Sun, Weijing

Publication type:

Article

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma

Published in:

Leukemia & Lymphoma, 2015, v. 56, n. 6, p. 1763, doi. 10.3109/10428194.2014.974040

By:

Papadopoulos, Kyriakos P.;
Egile, Coumaran;
Ruiz-Soto, Rodrigo;
Jiang, Jason;
Shi, Weiliang;
Bentzien, Frauke;
Rasco, Drew;
Abrisqueta, Pau;
Vose, Julie M.;
Tabernero, Josep

Publication type:

Article